Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years

NCT02215863 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT02215863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years
Lead sponsor
Korea University Guro Hospital
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2014
Completion date
March 31, 2015
Enrollment
1,195 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, streptococcus pneumoniae